SPRYARS Pharmaceuticals, Inc.
$4.57-56% 1Y
$4.57
$4.0752 weeks$13.06
SPRY in its own filings
Nothing in SPRY's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
129
Events found in the filings · across 543 filings · the record starts in 2020
- Hard flags
- none
Hard flags
- Most recent filing
- Aug 13, 2026
Most recent filing · Form 10-Q
- Record starts
- Oct 29, 2020
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 9, 2026
- SEC comment-letter activity17 occurrences
- 2024-11-25
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 13, 2026ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results.Earnings release · press release
- Jul 17, 2026On July 15, 2026, Richard Lowenthal resigned as a member of the Board of Directors (the “Board”) of ARS Pharmaceuticals, Inc. (the “Company”), effective immediately.Director or officer change · Form 8-K
- Jul 7, 2026On July 7, 2026, the Board of Directors (the “Board”) of ARS Pharmaceuticals, Inc. (the “Company”) appointed the Company’s current President Donn Casale as the Company’s Chief Executive Officer, effective immediately, replacing Richard Lowenthal in such capacity.Director or officer change · Form 8-K
- May 15, 2026ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update.Earnings release · press release
- May 13, 2026On May 12, 2026, the Board of Directors of ARS Pharmaceuticals, Inc., a Delaware corporation (the “Company”), based in part on the recommendation of Richard Lowenthal, the Company’s Chief Executive Officer, appointed Donn Casale as the Company’s President effective as of the date he commences employment with the …Director or officer change · Form 8-K
- Mar 9, 2026ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy ® (epinephrine nasal spray) Commercialization.Earnings release · press release
- Nov 10, 2025ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy ® (epinephrine nasal spray)Earnings release · press release
- Sep 29, 2025On September 29, 2025, ARS Pharmaceuticals, Inc. (the “Company”) and certain direct and indirect subsidiaries of the Company who may become a party thereto from time to time, as guarantors (the “Guarantors”), and ARS Pharmaceuticals Operations, Inc., a wholly owned subsidiary of the Company, as the borrower (the …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…